Affimed Announces Annual General Meeting of Shareholders
May 24 2022 - 6:30AM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, announced today that its
2022 Annual General Meeting of Shareholders (the “Annual Meeting”)
will be held on June 22, 2022 at 09:00 a.m. CET at the Radisson Blu
Hotel, Amsterdam City Center, Rusland 17, 1012 CK Amsterdam, the
Netherlands.
The notice and agenda of the Annual Meeting are available on
Affimed’s website
at https://www.affimed.com/investors/corporate-governance/
under “AGM”, as well as the SEC’s website at www.sec.gov.
About Affimed N.V.Affimed (Nasdaq: AFMD) is a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer by actualizing the
untapped potential of the innate immune system. The company’s
proprietary ROCK® platform enables a tumor-targeted approach to
recognize and kill a range of hematologic and solid tumors,
enabling a broad pipeline of wholly-owned and partnered single
agent and combination therapy programs. The ROCK® platform
predictably generates customized innate cell engager (ICE®)
molecules, which use patients’ immune cells to destroy tumor cells.
This innovative approach enabled Affimed to become the first
company with a clinical-stage ICE®. Headquartered in Heidelberg,
Germany, with offices in New York, NY, Affimed is led by an
experienced team of biotechnology and pharmaceutical leaders united
by a bold vision to stop cancer from ever derailing patients’
lives. For more about the company’s people, pipeline and partners,
please visit: www.affimed.com.
Investor Relations ContactAlexander
FudukidisDirector, Head of Investor
Relationsa.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024